The company's shares have tripled since the U.S. launch of Wegovy in June 2021. CEO Lars Fruergaard Jorgensen anticipates an increased proportion of U.S. patients continuing the weekly injection for over a year as supply constraints ease. Jorgensen also expects a growing adoption of obesity drugs as prices decrease over time, balancing with the introduction of new medicine generations that may justify higher prices in specific segments. Addressing potential regulatory scrutiny, head of business development David Moore acknowledged the uncertainty regarding the U.S. regulatory review of Novo's acquisition of three factories from Catalent Inc CTLT.